Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
AUSTRALIAN CLINICAL LABS LIMITED (ACL)ASX AI Signals has generated 5 signal for ACL during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest ACL Signals | |
| 19/05/2026 | SELL |
| 15/05/2026 | SELL |
| 27/04/2026 | SELL |
ACL Share Price | |
| Current Price | $2.240 |
| 52 Week High | $2.869 |
| 52 Week Low: | $1.835 |
| Trading at (% of 52 Week High) | 78.08% |
Australian Clinical Labs Limited (ASX: ACL) is a pathology services company operating in Australia. It provides a wide range of diagnostic testing and medical laboratory services to hospitals, medical practitioners, and patients. The company focuses on delivering accurate and timely clinical testing to support healthcare decisions.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
The SELL recommendation for AUSTRALIAN CLINICAL LABS LIMITED (ACL) is supported by technical indicators signaling downward momentum and potential overvaluation at the current price of 1.8350. Market conditions and sector-specific challenges contribute to a heightened risk profile, justifying a high confidence level in the SELL signal.
As the Australian market shows signs of recovery, with the ASX 200 futures indicating a potential uptick, investors are keeping a close eye on various opportunities. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those looking to diversify their portfol As the Australian market winds down for the year, experiencing a slight dip amid holiday profit-taking, investors are turning their attention to potential opportunities in the new year. Penny stocks, despite being an older term, continue to capture interest due to their potential for growth at lower The Australian market is facing a challenging period, with the ASX 200 futures indicating a significant drop following recent U.S. economic disruptions and domestic political shifts affecting investor sentiment. Despite these hurdles, opportunities still exist for investors willing to explore less c As the Australian market rebounds, with the ASX showing positive momentum and gold reaching new highs, investors are keenly observing opportunities across various sectors. Penny stocks, though an old term, continue to capture attention as they often represent smaller or newer companies that can offe The Australian market has been experiencing a much-needed pause after a year of breaking records, with staples and utilities recently leading gains while other sectors faced challenges. In such fluctuating conditions, identifying promising investments requires careful consideration of financial streLatest AUSTRALIAN CLINICAL LABS LIMITED(ACL) News
3 ASX Penny Stocks With Market Caps Under A$600M To Consider
ASX Penny Stocks To Watch In January 2026
ASX Penny Stocks To Watch In November 2025
3 ASX Penny Stocks With Market Caps Under A$3B To Consider
3 Promising ASX Penny Stocks With Market Caps Under A$2B
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial